Table 2. Crude seropositivity, adjusted seroprevalence, and relative risk of seropositivity by age and sex from survey of seroprevalence of SARS-CoV-2 IgG in Juba, South Sudan.*.
| Category | No. | No. (%) positive | No. (%) negative | Seroprevalence (95% CrI) | Relative risk (95% CrI) |
|---|---|---|---|---|---|
| Overall |
1,840 |
411 (22.3) |
1,429 (77.7) |
38.3 (31.8–46.5) |
|
| Age, y | |||||
| 1–4 | 68 | 20 (29.4) | 48 (70.6) | 43 (31.3–56.1) | 1.30 (0.96–1.71) |
| 5–9 | 224 | 52 (23.2) | 172 (76.8) | 39.3 (29.5–51.1) | 1.19 (0.92–1.51) |
| 10–19 | 448 | 124 (27.7) | 324 (72.3) | 44.9 (36.3–56) | 1.36 (1.11–1.66) |
| 20–29 | 459 | 89 (19.4) | 370 (80.6) | 33.3 (25.6–42) | Referent |
| 30–39 | 307 | 52 (16.9) | 255 (83.1) | 30 (21.9–39.3) | 0.91 (0.68–1.17) |
| 40–49 | 139 | 26 (18.7) | 113 (81.3) | 33.2 (22.8–45.6) | 1.00 (0.71–1.35) |
| 50–64 | 120 | 31 (25.8) | 89 (74.2) | 42.8 (30.6–57.6) | 1.29 (0.94–1.73) |
| 65–84 |
75 |
17 (22.7) |
58 (77.3) |
38.8 (25.2–54.8) |
1.17 (0.78–1.63) |
| Sex | |||||
| F | 1,149 | 260 (22.6) | 889 (77.4) | 33.3 (25.6–42) | Referent |
| M | 691 | 151 (21.9) | 540 (78.1) | 31.7 (23.6–41.2) | 0.95 (0.81–1.12) |
*NA, not available; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.